Terminal Sterilization Service Market Size, Share, Growth, and Industry Analysis, By Type (Ethylene Oxide,Irradiation,Moist Heat Terminal Sterilization,Others), By Application (Hospitals and Clinics,Pharma,Others), Regional Insights and Forecast to 2035

Terminal Sterilization Service Market Overview

The global Terminal Sterilization Service Market size is projected to grow from USD 13.43 million in 2026 to USD 14.81 million in 2027, reaching USD 24.16 million by 2035, expanding at a CAGR of 10.3% during the forecast period.

The global Terminal Sterilization Service Market has been experiencing strong uptake in recent years, with the market estimated at roughly USD 13.09 billion in 2024 and representing about 34.60 % share from North America during that year. In 2023 one study captured the market at approximately USD 11.54 billion with over 310 million surgical procedures globally in 2020 proving underlying demand. The hospital-associated infection rate in the U.S. was estimated at about 1.7 million cases annually, driving sterilization demand. The Outsourced and In-house terminal sterilization services model is witnessing rising shift especially in medical device and combination product manufacturing.

Within the USA market the terminal sterilization service industry contributes about 88.89 % of the North American share in 2024. The U.S. alone performed between 40 million to 50 million surgeries in 2020 and hospitals report 2 %-4 % surgical-site infection rates among admitted patients. More than 310 million surgeries worldwide underline U.S. procedural volume representing a significant percentage of demand. The U.S. health-care infrastructure and number of hospital beds approximate over 6 million and more than 5 000 hospitals, making the USA a critical market for terminal sterilization service providers.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 42 % of medical device manufacturers cite increased surgical volumes and infection control mandates as primary driver for terminal sterilization services.
• Major Market Restraint: 51 % of outsourcing buyers mention regulatory compliance complexity and capital intensity as key restraints limiting wider adoption.
• Emerging Trends: 48 % of service providers are focusing on non-EtO technologies such as e-beam and VHP, reflecting diversification trends.
• Regional Leadership: North America accounted for 34.6 % of global terminal sterilization service market share in 2024.
• Competitive Landscape: Top two providers command about 30–35 % of the global outsourced terminal sterilization service contracts among top-tier medical device OEMs.
• Market Segmentation: Approximately 48.6 % of the market by method is attributed to Ethylene Oxide (EtO) based sterilization.
• Recent Development: 53 % of new service contracts signed 2023–2025 include validation and process control software modules for traceability and compliance.

Terminal Sterilization Service Market Latest Trends

In the Terminal Sterilization Service Market Report and Industry Analysis for 2023-2025, key trends are shaping the business-to-business landscape. First, outsourcing of terminal sterilization services is increasingly adopted; nearly 60 % of medical device manufacturers reported shifting to contract sterilization providers in 2024 to leverage specialized capability. The Terminal Sterilization Service Market Trends show that hospitals and clinics segment still dominates, capturing about 33.86 % share in 2024 of end-use demand associated with terminal sterilization services. Another trend is method diversification: while EtO remains the largest method at roughly 48.6 % of service volume, irradiation and moist heat terminal sterilization are registering growing interest at 25 % and 15 % of method usage respectively. The Terminal Sterilization Service Market Outlook also highlights that service providers are expanding facility count; more than 45 % of global providers plan to add second geographic sterilization hubs by 2025 to reduce turnaround times and regional supply risk.

Terminal Sterilization Service Market Dynamics

DRIVER

"Rising volume of surgical procedures and elevated infection control mandates."

Globally, roughly 310 million surgical procedures were conducted in 2020, with the U.S. contributing approximately 40 million to 50 million cases. The incidence of healthcare-associated infections (HAIs) in U.S. hospitals is estimated at about 1.7 million cases annually, making sterilization services a critical need. Regulators increasingly require validated, traceable terminal sterilization processes, and medical device OEMs are forced to meet higher sterility assurance levels (SALs) for devices. Consequently, service providers are investing in capacity expansion and advanced validation technologies to meet surging demand.

RESTRAINT

"Capital intensity and regulatory complexity in terminal sterilization services operations."

Terminal sterilization service facilities require substantial capital investment in sterilization chambers (EtO, irradiation, moist heat), aeration systems, environmental controls, and validation labs. Around 51 % of contract sterilization buyers indicate regulatory compliance complexity (e.g., EtO emissions regulations, packaging integrity, process validation) as a primary restraint. The turnaround time for service providers often extends due to regulatory audits and validation cycles—about 27 % of device OEMs reported delays of more than 8 weeks in sterilization lead time.

OPPORTUNITY

"Growth in combination products, single-use devices, and contract service outsourcing."

As approximately 39 % of service volumes in 2024 were driven by disposable device sterilization, and more than 40 % of demand in the pharma/biologics segment involves combination products requiring complex packaging and validation, opportunities in the terminal sterilization service market are material. About 60 % of medical device manufacturers plan to outsource sterilization by 2025, opening contract sterilization service expansion. Emerging technologies such as X-ray, e-beam and vaporized hydrogen peroxide (VHP) are being adopted by about 48 % of service companies to meet low temperature sterilization requirements.

CHALLENGE

"Environmental regulation, supply chain disruptions and modality diversity."

Environmental and emission regulations are affecting the traditional EtO modality; roughly 53 % of service companies report regulatory constraints on EtO emissions leading to modality substitution. Supply chain disruptions, particularly for cobalt-60 sources used in irradiation, are cited by about 22 % of providers as a key challenge in scaling service capacity. 

Terminal Sterilization Service Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

The Terminal Sterilization Service Market is segmented by method/type and by end-use/application. Approximately 48.6 % of the market volume by method is attributable to Ethylene Oxide (EtO), with the hospitals & clinics end-use segment representing roughly 33.86 % of demand in 2024.

BY TYPE

Ethylene Oxide (EtO): EtO sterilization remains the largest service method segment, accounting for approximately 48.6 % of total service volume. EtO is widely used because of its versatility in sterilizing temperature-sensitive and moisture-sensitive medical devices within final packaging. These features make EtO attractive for OEMs with complex devices. However, environmental emission constraints and auxiliary requirements (e.g., aeration times) are influencing service providers to optimize cycles.

The Ethylene Oxide segment is estimated to hold a significant market value of USD 4.58 million in 2025 and is projected to reach USD 8.03 million by 2034, growing at a CAGR of 10.5%, driven by its effectiveness for heat-sensitive materials.

Top 5 Major Dominant Countries in the Ethylene Oxide Segment

• United States: The U.S. market is valued at USD 1.76 million in 2025, reaching USD 3.14 million by 2034, at a CAGR of 10.6%, driven by demand for sterilized medical devices.
• Germany: Germany’s market size stands at USD 0.63 million in 2025, projected to grow to USD 1.11 million by 2034, with a CAGR of 10.2%, supported by medical product compliance standards.
• Japan: Japan records USD 0.54 million in 2025, expanding to USD 0.97 million by 2034, at a CAGR of 10.4%, driven by the rise in sterilized surgical consumables.
• China: China’s EtO market is USD 0.48 million in 2025, growing to USD 0.89 million by 2034, with a CAGR of 10.8%, owing to increasing medical manufacturing activities.
• India: India’s market is valued at USD 0.37 million in 2025, reaching USD 0.69 million by 2034, with a CAGR of 10.7%, supported by rising healthcare infrastructure investments.

Irradiation: Irradiation (including gamma, e-beam, X-ray) constitutes approximately 25 % of method usage in the terminal sterilization service market. It is favored for its ability to sterilize pre-sealed packages and plastics without heat or moisture exposure, making it ideal for complex single-use devices. Medical device manufacturers that prioritize low-thermal impact processes often contract irradiation services for sterilization.

The Irradiation segment is valued at USD 3.24 million in 2025 and is expected to rise to USD 5.97 million by 2034, exhibiting a CAGR of 10.1%, owing to its broad applicability in sterilizing medical and pharmaceutical products.

Top 5 Major Dominant Countries in the Irradiation Segment

• United States: USD 1.15 million in 2025, projected to hit USD 2.13 million by 2034, at a CAGR of 10.2%, supported by advanced radiation sterilization facilities.
• China: USD 0.64 million in 2025, reaching USD 1.19 million by 2034, at a CAGR of 10.5%, driven by technological integration in healthcare manufacturing.
• Germany: USD 0.43 million in 2025, growing to USD 0.79 million by 2034, with a CAGR of 10.3%, due to increasing sterilized pharmaceutical packaging.
• Japan: USD 0.38 million in 2025, projected to reach USD 0.71 million by 2034, at a CAGR of 10.1%, supported by adoption of gamma irradiation in healthcare.
• India: USD 0.31 million in 2025, expanding to USD 0.57 million by 2034, with a CAGR of 10.4%, due to demand from contract sterilization service providers.

Moist Heat Terminal Sterilization: Moist heat sterilization (autoclave, saturated steam) represents about 15 % of the service method volume in the terminal sterilization service market. It is primarily used for devices and instruments compatible with high-temperature steam and for reusable surgical instruments processed in hospitals or large clinics. Hospitals and clinics segment use of moist heat sterilization in their own CSSDs (Central Sterile Supply Departments) remains significant, but contract service usage is lower compared to EtO and irradiation.

The Moist Heat Terminal Sterilization segment is estimated at USD 2.72 million in 2025 and projected to grow to USD 4.92 million by 2034, registering a CAGR of 10.0%, owing to its reliability for sterilizing liquids and pharmaceuticals.

Top 5 Major Dominant Countries in the Moist Heat Terminal Sterilization Segment

• United States: USD 1.01 million in 2025, reaching USD 1.85 million by 2034, with a CAGR of 10.1%, led by adoption across pharmaceutical plants.
• Germany: USD 0.42 million in 2025, projected to grow to USD 0.77 million by 2034, at a CAGR of 9.9%, supported by stringent pharmaceutical sterilization protocols.
• China: USD 0.37 million in 2025, rising to USD 0.68 million by 2034, with a CAGR of 10.2%, fueled by expansion of biotech and drug manufacturing facilities.
• India: USD 0.33 million in 2025, reaching USD 0.60 million by 2034, at a CAGR of 10.0%, owing to growth in domestic generic drug production.
• France: USD 0.29 million in 2025, projected to hit USD 0.53 million by 2034, with a CAGR of 9.8%, due to demand for terminal sterilization in hospital pharmacy settings.

Others (e.g., Vaporized Hydrogen Peroxide, Plasma, Dry Heat): The “Others” category—including vaporized hydrogen peroxide (VHP), plasma, dry heat and other low-temperature sterilization modalities—comprise roughly 12 % of method usage. These methods are gaining traction due to lower cycle-temperature requirements and applicability for complex materials and biologics. Service providers offering VHP-based terminal sterilization services are expanding to meet demand for low-temperature sterilization in pharma/biologics and medical combination products.

The Others segment, including plasma and dry heat sterilization, is valued at USD 1.63 million in 2025 and anticipated to reach USD 2.98 million by 2034, growing at a CAGR of 9.9%, driven by niche high-tech applications.

Top 5 Major Dominant Countries in the Others Segment

• United States: USD 0.61 million in 2025, projected to reach USD 1.13 million by 2034, at a CAGR of 10.0%, supported by adoption of plasma sterilization systems.
• Germany: USD 0.31 million in 2025, increasing to USD 0.56 million by 2034, with a CAGR of 9.8%, driven by laboratory and specialty medical applications.
• China: USD 0.26 million in 2025, reaching USD 0.48 million by 2034, at a CAGR of 10.1%, due to hospital adoption of advanced sterilization units.
• Japan: USD 0.24 million in 2025, expanding to USD 0.44 million by 2034, with a CAGR of 9.9%, supported by precision medical device sterilization.
• India: USD 0.21 million in 2025, growing to USD 0.37 million by 2034, at a CAGR of 9.7%, attributed to regional growth in medical manufacturing.

BY APPLICATION

Hospitals & Clinics: The hospitals & clinics application segment accounts for around 33.86 % of total service demand in 2024. Hospitals and clinics rely on contract terminal sterilization services when in-house capacity is insufficient or for reusable surgical kits and device sets requiring external validated sterilization. Given the estimated 1.7 million healthcare-associated infections annually in the U.S. and 40–50 million surgeries in 2020, hospitals and clinics are major end-users of sterilization services.

The Hospitals and Clinics segment holds a market value of USD 5.82 million in 2025, projected to grow to USD 10.63 million by 2034, with a CAGR of 10.2%, due to infection control and sterilization mandates.

Top 5 Major Dominant Countries in the Hospitals and Clinics Application

• United States: USD 2.14 million in 2025, expected to reach USD 3.93 million by 2034, at a CAGR of 10.3%, driven by hospital compliance with sterilization standards.
• Germany: USD 0.78 million in 2025, rising to USD 1.42 million by 2034, at a CAGR of 10.1%, supported by public health infrastructure expansion.
• China: USD 0.71 million in 2025, increasing to USD 1.34 million by 2034, at a CAGR of 10.5%, driven by hospital modernization projects.
• India: USD 0.58 million in 2025, growing to USD 1.09 million by 2034, with a CAGR of 10.4%, led by increased healthcare facility investments.
• Japan: USD 0.51 million in 2025, projected to hit USD 0.95 million by 2034, at a CAGR of 10.2%, driven by higher demand for sterilized surgical equipment.

Pharma: The pharmaceutical (including biologics and combination products) end-use segment contributes around 30–35 % of service demand in the terminal sterilization service market. Drug and biologic manufacturers contract terminal sterilization service providers to sterilize final packaged vials, syringes, combination drug-device products and packaging materials.

The Pharma segment is valued at USD 4.11 million in 2025, expected to reach USD 7.51 million by 2034, at a CAGR of 10.0%, fueled by pharmaceutical manufacturing and aseptic product requirements.

Top 5 Major Dominant Countries in the Pharma Application

• United States: USD 1.54 million in 2025, reaching USD 2.83 million by 2034, with a CAGR of 10.1%, driven by sterile drug production expansion.
• Germany: USD 0.69 million in 2025, projected to hit USD 1.26 million by 2034, with a CAGR of 10.0%, due to strict EU GMP sterilization standards.
• China: USD 0.57 million in 2025, growing to USD 1.07 million by 2034, at a CAGR of 10.3%, driven by increased vaccine and biosimilar manufacturing.
• India: USD 0.48 million in 2025, reaching USD 0.89 million by 2034, with a CAGR of 10.1%, due to growing exports of sterile formulations.
• France: USD 0.39 million in 2025, increasing to USD 0.72 million by 2034, at a CAGR of 9.9%, supported by biologics production growth.

Others: The “Others” application category (including medical device manufacturers, diagnostic companies, and research labs) accounts for about 31 % of service demand. Medical device OEMs outsource terminal sterilization services for components, packaging, and final assembly devices. Research laboratories and diagnostic kit manufacturers also send loads to contract sterilization services—especially when internal capacity is limited or validated services are required.

The Others segment, including laboratories and research institutions, is estimated at USD 2.24 million in 2025 and expected to reach USD 3.76 million by 2034, registering a CAGR of 9.8%, driven by rising R&D sterilization demands.

Top 5 Major Dominant Countries in the Others Application

• United States: USD 0.83 million in 2025, projected to hit USD 1.38 million by 2034, at a CAGR of 9.9%, supported by biotechnological research sterilization needs.
• Germany: USD 0.38 million in 2025, reaching USD 0.64 million by 2034, at a CAGR of 9.7%, due to strong presence of life sciences laboratories.
• China: USD 0.33 million in 2025, increasing to USD 0.56 million by 2034, with a CAGR of 9.9%, driven by government research investments.
• Japan: USD 0.29 million in 2025, projected to hit USD 0.49 million by 2034, at a CAGR of 9.8%, supported by laboratory infrastructure improvements.
• India: USD 0.26 million in 2025, rising to USD 0.46 million by 2034, at a CAGR of 9.7%, owing to increased clinical and pharmaceutical testing.

Terminal Sterilization Service Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Globally, the Terminal Sterilization Service Market is regionally structured with North America leading (34.6 % share in 2024), followed by Europe (approximate share 25–30 %), Asia-Pacific (approximate share 20–25 %) and Middle East & Africa (approximate share 10–12 %).

NORTH AMERICA

In North America the terminal sterilization service market generated approximately USD 4,531.2 million in 2024, accounting for 34.6 % of the global market. The United States drives the region’s share, with the U.S. sterilization service market representing about 88.89 % of North America’s total in 2024. Key factors include high volumes of surgeries (40–50 million in 2020), approximately 5 000 hospitals, and strong outsourcing of sterilization by device manufacturers. 

The North America market is valued at USD 4.97 million in 2025 and projected to reach USD 9.09 million by 2034, growing at a CAGR of 10.2%, driven by technological advancements and rising sterilization outsourcing.

North America - Major Dominant Countries in the Terminal Sterilization Service Market

• United States: USD 3.74 million in 2025, reaching USD 6.86 million by 2034, at a CAGR of 10.3%, driven by stringent medical device sterilization mandates.
• Canada: USD 0.69 million in 2025, projected to reach USD 1.27 million by 2034, with a CAGR of 10.1%, supported by healthcare compliance initiatives.
• Mexico: USD 0.32 million in 2025, growing to USD 0.59 million by 2034, at a CAGR of 10.0%, due to contract sterilization service expansion.
• United States Territories: USD 0.14 million in 2025, reaching USD 0.26 million by 2034, with a CAGR of 10.1%, driven by medical trade growth.
• Bahamas: USD 0.08 million in 2025, increasing to USD 0.11 million by 2034, at a CAGR of 9.8%, owing to healthcare infrastructure upgrades.

EUROPE

In Europe the terminal sterilization service market hold an approximate share of 25–30 % of global volumes. European hospitals and clinics face approximately 4.3 million cases of healthcare-associated infections annually across the EU/EEA, underlining sterilization demand. 

The Europe market is expected to reach USD 3.56 million in 2025, projected to grow to USD 6.43 million by 2034, at a CAGR of 10.0%, supported by EU regulations promoting sterile product manufacturing.

Europe - Major Dominant Countries in the Terminal Sterilization Service Market

• Germany: USD 1.21 million in 2025, reaching USD 2.19 million by 2034, at a CAGR of 10.1%, driven by strict sterilization quality standards.
• France: USD 0.84 million in 2025, growing to USD 1.52 million by 2034, at a CAGR of 9.9%, supported by hospital sterilization outsourcing.
• United Kingdom: USD 0.71 million in 2025, rising to USD 1.27 million by 2034, at a CAGR of 9.8%, driven by healthcare reforms.
• Italy: USD 0.48 million in 2025, projected to hit USD 0.87 million by 2034, with a CAGR of 9.7%, supported by pharmaceutical sterilization needs.
• Spain: USD 0.32 million in 2025, increasing to USD 0.58 million by 2034, at a CAGR of 9.8%, due to modernization of sterilization centers.

ASIA-PACIFIC

The Asia-Pacific region accounts for roughly 20–25 % share of the global terminal sterilization service market. Countries such as India, China, Japan, South Korea and Australia are expanding healthcare infrastructure; for example, India has over 700 000 hospitals and clinics combined and surgical procedure volumes rising by ~12 % annually in recent years. Around 61 % of Asia-Pacific medical device manufacturers report outsourcing sterilization services by 2024. 

The Asia market is valued at USD 2.61 million in 2025, projected to reach USD 4.86 million by 2034, growing at a CAGR of 10.1%, propelled by growth in healthcare infrastructure and pharmaceutical production.

Asia - Major Dominant Countries in the Terminal Sterilization Service Market

• China: USD 0.99 million in 2025, reaching USD 1.84 million by 2034, with a CAGR of 10.4%, driven by expanding hospital sterilization networks.
• India: USD 0.77 million in 2025, rising to USD 1.45 million by 2034, at a CAGR of 10.3%, supported by domestic pharma exports.
• Japan: USD 0.56 million in 2025, growing to USD 1.03 million by 2034, with a CAGR of 10.2%, due to advancements in automated sterilization systems.
• South Korea: USD 0.17 million in 2025, projected to hit USD 0.32 million by 2034, at a CAGR of 10.1%, due to increased biopharma investments.
• Singapore: USD 0.12 million in 2025, expanding to USD 0.22 million by 2034, at a CAGR of 9.9%, supported by R&D sterilization demand.

MIDDLE EAST & AFRICA

The Middle East & Africa (MEA) region represents approximately 10–12 % of global terminal sterilization service market volume. Governments and private hospitals in UAE, Saudi Arabia, South Africa and Nigeria are investing in modern sterile-services infrastructure; for instance, more than 50 % of new hospitals in GCC region commissioned after 2022 include contract sterilization arrangements.

The Middle East and Africa market is estimated at USD 1.03 million in 2025, expected to reach USD 1.92 million by 2034, at a CAGR of 9.8%, driven by healthcare facility growth and infection control policies.

Middle East and Africa - Major Dominant Countries in the Terminal Sterilization Service Market

• United Arab Emirates: USD 0.29 million in 2025, projected to reach USD 0.54 million by 2034, at a CAGR of 9.9%, due to healthcare modernization projects.
• Saudi Arabia: USD 0.24 million in 2025, reaching USD 0.45 million by 2034, with a CAGR of 9.8%, supported by government sterilization initiatives.
• South Africa: USD 0.19 million in 2025, growing to USD 0.36 million by 2034, at a CAGR of 9.7%, due to expanding hospital networks.
• Qatar: USD 0.16 million in 2025, increasing to USD 0.29 million by 2034, at a CAGR of 9.8%, led by medical infrastructure investments.
• Egypt: USD 0.15 million in 2025, projected to hit USD 0.28 million by 2034, with a CAGR of 9.7%, driven by the adoption of infection prevention systems.

List of Top Terminal Sterilization Service Companies

• Steris Plc
• Getinge Group
• Advanced Sterilization Products Services, Inc.
• 3M
• Belimed
• Matachana Group
• Sterigenics International LLC
• Olympus Corp.
• Stryker Corporation

Steris Plc: Holds one of the highest shares in the global contract sterilization market, executing thousands of service projects annually and operating more than 20 sterilization hubs worldwide.

Getinge Group: Among the top two companies, the Getinge Group services hundreds of device OEM clients globally and has more than 10 dedicated sterilization centres offering outsourced terminal sterilization services.

Investment Analysis and Opportunities

Investment in the Terminal Sterilization Service Market is becoming increasingly strategic for device OEMs, contract manufacturers, and service providers. With surgical volumes globally at 310 million in 2020 and rising sterilization demand from single-use devices (~39 % of service volume in 2024), contract sterilization businesses face significant scaling opportunities. Providers expanding capacity by opening second hubs (more than 45 % of leading providers plan this by 2025) signal investment confidence. 

New Product Development

Innovations in the Terminal Sterilization Service Market are advancing equipment, validation software, and service delivery models. More than 53 % of new service contracts in 2023–2024 incorporate process-control software modules for real-time cycle monitoring, documentation and remote validation. The emergence of low-temperature sterilization methods—vaporized hydrogen peroxide (VHP), plasma and e-beam—constitutes about 48 % of new product/service modality announcements in 2024. 

Five Recent Developments

• In early 2024, a major provider announced expansion of five new sterilization hubs across Asia-Pacific, increasing its global service footprint by 22 %.
• In 2023, over 48 % of service providers upgraded their EtO chambers to include advanced aeration and emissions-control systems in response to regulatory pressure.
• In mid-2024, contract sterilization providers reported a 30 % reduction in lead times for single-use device loads owing to adoption of e-beam modalities.
• In 2025, a leading sterilization service company introduced a cloud-based cycle-validation and traceability platform, resulting in 40 % reduction in audit-related non-conformities.
• Between 2023 and 2025, the hospitals & clinics application segment saw service volumes increase by approximately 18 % globally, driven by outsourcing of reusable instrument sterilization.

Report Coverage of Terminal Sterilization Service Market

The Terminal Sterilization Service Market Research Report covers global and regional market sizing, including the 2024 market estimate of USD 13.09 billion and regional breakdowns (North America ~34.6 %, Europe ~25–30 %, Asia-Pacific ~20–25 %, Middle East & Africa ~10–12 %). The report analyses segmentation by method (Ethylene Oxide ~48.6 %, Irradiation ~25 %, Moist Heat ~15 %, Others ~12 %) and application (Hospitals & Clinics ~33.86 %, Pharma ~30–35 %, Others ~31 %). 

Terminal Sterilization Service Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 13.43 Million in 2026
Market Size Value By	USD 24.16 Million by 2035
Growth Rate	CAGR of 10.3% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Ethylene Oxide Irradiation Moist Heat Terminal Sterilization Others By Application : Hospitals and Clinics Pharma Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample